Highlights Tenaya Therapeutics, Inc.

Stocks

TNYA

US87990A1060

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-07-10 pm EDT			5-day change	1st Jan Change
0.8704 ^USD	+2.40%		+10.61%	+22.33%

Jun. 29	Tenaya Therapeutics, Inc. Announces Management Changes, Effective July 13, 2026	CI
Jun. 29	Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026	CI

Highlights

Jun. 02	Tenaya Therapeutics, Inc. Announces New Interim Data From MyPEAK-1 Phase 1b/2 Trial Of TN-201 For Adults With MYBPC3-Associated HCM	CI
May. 15	Tenaya Therapeutics Presents Interim Data From Ridge-1 Phase 1b/2 Clinical Trial Of TN-401 Gene Therapy For PKP2-Associated ARVC	CI
May. 06	Tenaya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 27	Tenaya Therapeutics Announces New Clinical Data and Pipeline Innovations	CI
Mar. 11	Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 09	Tenaya Therapeutics Presents Preclinical Data Highlighting Tn-301?S Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy	CI
Mar. 05	Tenaya Therapeutics and Alnylam Pharmaceuticals Enter Research Collaboration Agreement	CI
Mar. 05	Tenaya Therapeutics Signs Potential $1.13 Billion Deal With Alnylam	MT
Jan. 09	Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones	CI
Dec. 11	Tenaya Therapeutics Says FDA Hold Lifted on Heart Disease Trial	DJ
Dec. 11	Tenaya Therapeutics, Inc. Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy	CI
Dec. 11	Tenaya Therapeutics, Inc. Reports Positive Interim Data From RIDGE-1 Phase 1b/2 Clinical Trial Of TN-401 Gene Therapy For Adults With PKP2-Associated ARVC	CI
Dec. 11	Tenaya Therapeutics, Inc. Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1?? Phase 1b/2a Clinical Trial of TN-201 Gene Therapy	CI
Nov. 10	Tenaya Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 08	Tenaya Therapeutics Presents Promising Interim Clinical Data from Mypeak??-1 Phase 1B/2A Clinical Trial of Tn-201 Gene Therapy for the Treatment of Mybpc3-Associated Hypertrophic Cardiomyopathy	CI
Nov. 07	US FDA places clinical hold on Tenaya gene therapy trial for rare heart disease	RE
Nov. 07	Tenaya Therapeutics Inc - FDA places clinical hold on Tenaya's MyPeak-1 trial - SEC filing	RE
Nov. 07	US FDA places clinical hold on Tenaya Therapeutics' gene therapy	RE
Nov. 07	FDA Clinical Hold on Phase 1B/2A Trial for TN-201 with Protocol Amendment Request	CI
Nov. 04	Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy Will Be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025	CI
25-09-18	Tenaya Therapeutics reports inducement grants	RE
25-08-06	Tenaya Therapeutics Q2 net loss of $23.3 narrows	RE
25-08-06	Tenaya Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-07-30	Tenaya Therapeutics, Inc. Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed	CI
25-05-13	Tenaya Therapeutics, Inc. to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting	CI